Postoperative management for non-small cell lung cancer harboring EGFR mutations

Ítems similars

• Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
  per: Kuwata, Taiji, et al.
  Publicat: (2016)
• Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer
  per: Shinohara, Shinji, et al.
  Publicat: (2018)
• Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
  per: Tanaka, Satomi, et al.
  Publicat: (2019)
• Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations
  per: Zhang, Minghui, et al.
  Publicat: (2016)
• Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations
  per: Alfredo Addeo
  Publicat: (2022-06-01)